Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00171106
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 18, 2016
Information provided by:

Brief Summary:
This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure

Condition or disease Intervention/treatment Phase
Diastolic Dysfunction, Symptomatic Heart Failure Drug: valsartan Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure
Study Start Date : December 2002
Primary Completion Date : August 2007
Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Valsartan
U.S. FDA Resources

Primary Outcome Measures :
  1. Change in baseline exercise test after 15-42 days and 14 weeks

Secondary Outcome Measures :
  1. Oxygen consumption during the exercise test
  2. Exercise test blood pressure
  3. Borg score of breathlessness
  4. 6-minute walk test at baseline and after 14 weeks
  5. Quality of life assessment at baseline and after 14 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Symptomatic diastolic heart failure
  • Breathlessness with physical exertion

Exclusion Criteria:

  • Uncontrolled hypertension
  • Asthma, COPD, or abnormal lung function
  • History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
  • Liver, kidney, or pancreas disease
  • Allergy to valsartan

Other protocol-defined exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00171106

Investigative Centers, Germany
Novartis Pharmaceuticals
Basel, Switzerland
Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Additional Information:
Publications of Results: Identifier: NCT00171106     History of Changes
Other Study ID Numbers: CVAL489B2401
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: November 18, 2016
Last Verified: November 2016

Keywords provided by Novartis:
diastolic dysfunction
heart failure
exercise tolerance

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action